Business Description
Travere Therapeutics Inc
NAICS : 325411
SIC : 2834
Compare
Compare
Traded in other countries / regions
17R.GermanyTVTX.USA IPO Date
2003-07-23Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.11 | |||||
| Equity-to-Asset | 0.06 | |||||
| Debt-to-Equity | 9.51 | |||||
| Debt-to-EBITDA | -1.74 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.23 | |||||
| Beneish M-Score | -3.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.1 | |||||
| 3-Year EBITDA Growth Rate | -13.1 | |||||
| 3-Year EPS without NRI Growth Rate | -8.1 | |||||
| 3-Year FCF Growth Rate | -24.6 | |||||
| 3-Year Book Growth Rate | -49.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.77 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.82 | |||||
| 9-Day RSI | 42.57 | |||||
| 14-Day RSI | 44.82 | |||||
| 6-1 Month Momentum % | -11.67 | |||||
| 12-1 Month Momentum % | -11.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.42 | |||||
| Quick Ratio | 3.37 | |||||
| Cash Ratio | 3.17 | |||||
| Days Inventory | 343.13 | |||||
| Days Sales Outstanding | 26.37 | |||||
| Days Payable | 737.75 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.42 | |||||
| Operating Margin % | -118.65 | |||||
| Net Margin % | -131.35 | |||||
| ROE % | -171.8 | |||||
| ROA % | -36.8 | |||||
| ROIC % | -100.56 | |||||
| ROC (Joel Greenblatt) % | -832.43 | |||||
| ROCE % | -42.47 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.31 | |||||
| PB Ratio | 31.06 | |||||
| EV-to-EBIT | -4.79 | |||||
| EV-to-EBITDA | -5.47 | |||||
| EV-to-Revenue | 6.03 | |||||
| EV-to-Forward-Revenue | 5.01 | |||||
| EV-to-FCF | -5.94 | |||||
| Earnings Yield (Greenblatt) % | -20.88 |
How Travere Therapeutics Inc (TVTX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TVTX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 212.018 | ||
| EPS (TTM) ($) | -4.37 | ||
| Beta | 0.34 | ||
| Volatility % | 25.48 | ||
| 14-Day RSI | 44.82 | ||
| 14-Day ATR ($) | 1.12215 | ||
| 20-Day SMA ($) | 21.4235 | ||
| 12-1 Month Momentum % | -11.35 | ||
| 52-Week Range ($) | 17.82 - 30.35 | ||
| Shares Outstanding (Mil) | 64.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Travere Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Travere Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Travere Therapeutics Inc Frequently Asked Questions
What is Travere Therapeutics Inc(TVTX)'s stock price today?
The current price of TVTX is $20.81. The 52 week high of TVTX is $30.35 and 52 week low is $17.82.
When is next earnings date of Travere Therapeutics Inc(TVTX)?
The next earnings date of Travere Therapeutics Inc(TVTX) is 2023-05-05 Est..
Does Travere Therapeutics Inc(TVTX) pay dividends? If so, how much?
Travere Therapeutics Inc(TVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
